首页> 外文期刊>New horizons in translational medicine. >Chemotherapeutic effect of 3, 3'-Diindolylmethane encapsulated chitosan nanoparticles on 7, 12-Dimethylbenz (a) anthracene induced mammary cancer - A dose dependent study
【24h】

Chemotherapeutic effect of 3, 3'-Diindolylmethane encapsulated chitosan nanoparticles on 7, 12-Dimethylbenz (a) anthracene induced mammary cancer - A dose dependent study

机译:3,3'-二吲哚甲烷甲烷包裹的壳聚糖纳米粒子对7,12-二甲基苯并(a)蒽诱导的乳腺癌的化学治疗-剂量依赖性研究

获取原文
获取原文并翻译 | 示例
       

摘要

Breast cancer is the second most prevalent cancer among women and its incidence is amplifying alarmingly. Since genetic factors are believed to account for only 10% of the reported cases, remaining the environmental factors, including diet are thought to play a significant role in predisposing breast cancer. Many bioactive compounds have been reported for their anticancer potential. One among the bioactive compound 3, 3'-Diindolylmethane (DIM) is a phytochemical possess a wide array of pharmacological activities such as anti-proliferative and anti-oxidant properties. Its properties such as poor water solubility and low bioavailability have hampered its clinical development. Therefore, it is a great interest to study whether the nano formulation for DIM with chitosan for its enhanced potential, the present study was aimed to evaluate the chemotherapeutic potential of 3, 3'- Diindolylmethane encapsulated chitosan nanoparticles (DIM@CS-NP) on 7,12-Dimethylbenz(a)anthracene (DMBA) induced mammary carcinoma in rats. DMBA was induced in a single subcutaneous injection of 25 mg/ kg body weight to each rat. In the present study, we investigated the altered activities of lipid peroxidation, enzymatic antioxidants (SOD, CAT, GPx) and non- enzymatic antioxidant (GSH) in plasma, liver and mammary tissue, supported by histopathological study of mammary tissues. We evaluated the changes in the body weight of control and experimental animals. There was a significant decrease in the final body weight of tumor bearing animals, when compared to control animals. Also, we observed a diminished cellular antioxidant status and the elevated oxidant levels in plasma, liver, mammary tissues of DMBA induced rats. However, administration of DIM@CS-NP significantly increased the mean final body weight when compared with DMBA induced animals. Oral supplementation of different doses of DIM@CS-NP (0.5, 1, 2 mg/kg BW), significantly renovated the activities of cellular antioxidants and ultimately diminished the levels of lipid peroxidation, which pointed towards suppression of preneoplastic lesions, thereby reduced the cancer risk, and significant improvement in the levels of enzymatic (SOD, CAT, GPx) and non- enzymatic antioxidant (GSH) in the plasma, liver and mammary tissue. Based on the above finding we conclude the nano formulation of DIM provides a novel therapeutic regime for mammary cancer.
机译:乳腺癌是女性中第二大流行癌症,其发病率正以惊人的速度增长。由于认为遗传因素仅占报告病例的10%,因此认为包括饮食在内的其余环境因素在易感性乳腺癌中起着重要作用。据报道许多生物活性化合物具有抗癌潜力。生物活性化合物3中的一种,3'-二吲哚基甲烷(DIM)是一种具有多种药理活性(例如抗增殖和抗氧化特性)的植物化学物质。它的性能,如水溶性差和生物利用度低,阻碍了其临床发展。因此,研究具有壳聚糖的DIM纳米制剂是否具有增强的潜力,引起了极大的兴趣,本研究旨在评估3,3'-二吲哚基甲烷包裹的壳聚糖纳米颗粒(DIM @ CS-NP)的化学治疗潜力。 7,12-二甲基苯并(a)蒽(DMBA)诱导大鼠乳腺癌。在每只大鼠皮下注射25 mg / kg体重时诱导DMBA。在本研究中,我们通过乳腺组织病理学研究,研究了血浆,肝脏和乳腺组织中脂质过氧化,酶促抗氧化剂(SOD,CAT,GPx)和非酶促抗氧化剂(GSH)的活性变化。我们评估了对照动物和实验动物体重的变化。与对照组动物相比,荷瘤动物的最终体重显着降低。此外,我们观察到DMBA诱导的大鼠血浆,肝脏,乳腺组织中的细胞抗氧化剂状态降低,氧化剂水平升高。但是,与DMBA诱导的动物相比,施用DIM @ CS-NP显着增加了平均最终体重。口服补充不同剂量的DIM @ CS-NP(0.5,1,2 mg / kg BW),可显着改善细胞抗氧化剂的活性,并最终降低脂质过氧化的水平,从而抑制肿瘤前病变,从而减少肿瘤的发生。罹患癌症的风险,以及血浆,肝脏和乳腺组织中的酶促(SOD,CAT,GPx)和非酶促抗氧化剂(GSH)含量显着提高。基于以上发现,我们得出结论,DIM的纳米制剂为乳癌提供了一种新颖的治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号